Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3,869 | 5 | 60.7% |
| Consulting Fee | $2,363 | 3 | 37.1% |
| Food and Beverage | $139.97 | 2 | 2.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $2,769 | 5 | $0 (2024) |
| iSchemaView, Inc. | $1,838 | 2 | $0 (2023) |
| InspireMD Ltd | $1,625 | 1 | $0 (2024) |
| Genentech USA, Inc. | $139.97 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,081 | 3 | InspireMD Ltd ($1,625) |
| 2023 | $2,275 | 4 | AbbVie Inc. ($1,313) |
| 2022 | $875.00 | 1 | iSchemaView, Inc. ($875.00) |
| 2018 | $127.53 | 1 | Genentech USA, Inc. ($127.53) |
| 2017 | $12.44 | 1 | Genentech USA, Inc. ($12.44) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | InspireMD Ltd | CGuard (Device) | — | Cash or cash equivalent | $1,625.00 | Research |
| Study: Safety and Efficacy of the CGuard Carotid Stent System in Carotid Artery Stenting (C-Guardians) • Category: Cardiology | ||||||
| 07/18/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $800.00 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke | ||||||
| 03/25/2024 | ABBVIE INC. | — | — | Cash or cash equivalent | $656.25 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke | ||||||
| 12/14/2023 | AbbVie Inc. | — | — | Cash or cash equivalent | $262.50 | Research |
| Study: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | ||||||
| 09/06/2023 | AbbVie Inc. | — | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| 07/31/2023 | AbbVie Inc. | — | — | Cash or cash equivalent | $525.00 | Research |
| Study: A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | ||||||
| 01/26/2023 | iSchemaView, Inc. | — | Consulting Fee | Cash or cash equivalent | $962.50 | General |
| 09/22/2022 | iSchemaView, Inc. | — | Consulting Fee | Cash or cash equivalent | $875.00 | General |
| 01/23/2018 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $127.53 | General |
| 02/27/2017 | Genentech USA, Inc. | Activase (Biological) | Food and Beverage | In-kind items and services | $12.44 | General |
| Category: Metabolism & Primary Care | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Safety and Efficacy of the CGuard Carotid Stent System in Carotid Artery Stenting (C-Guardians) | InspireMD Ltd | $1,625 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Ischemic Stroke | ABBVIE INC. | $1,456 | 2 |
| A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke | AbbVie Inc. | $787.50 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 2 | 26 | 42 | $8,689 | $2,803 |
| 2021 | 4 | 53 | 70 | $18,153 | $5,123 |
| 2020 | 7 | 107 | 150 | $39,838 | $10,838 |
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 13 | 19 | $4,675 | $1,545 | 33.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 13 | 23 | $4,014 | $1,257 | 31.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 14 | $6,666 | $1,962 | 29.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 31 | $5,365 | $1,763 | 32.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 14 | 14 | $4,202 | $775.74 | 18.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 11 | 11 | $1,920 | $622.86 | 32.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 18 | 41 | $11,316 | $3,306 | 29.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 16 | 16 | $7,552 | $2,403 | 31.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 16 | 35 | $5,915 | $1,981 | 33.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 12 | 12 | $4,911 | $979.57 | 19.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 21 | 21 | $4,236 | $811.64 | 19.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 12 | 12 | $2,064 | $679.92 | 32.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 12 | 13 | $3,844 | $676.60 | 17.6% |
About Dr. Eva Mistry, M.D
Dr. Eva Mistry, M.D is a Vascular Neurology healthcare provider based in Nashville, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2013. The National Provider Identifier (NPI) number assigned to this provider is 1205274024.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eva Mistry, M.D has received a total of $6,371 in payments from pharmaceutical and medical device companies, with $3,081 received in 2024. These payments were reported across 10 transactions from 4 companies. The most common payment nature is "" ($3,869).
As a Medicare-enrolled provider, Mistry has provided services to 186 Medicare beneficiaries, totaling 262 services with total Medicare billing of $18,764. Data is available for 3 years (2020–2022), covering 13 distinct procedure/service records.
Practice Information
- Specialty Vascular Neurology
- Other Specialties Neurology
- Location Nashville, TN
- Active Since 06/14/2013
- Last Updated 03/29/2022
- Taxonomy Code 2084V0102X
- Entity Type Individual
- NPI Number 1205274024
Products in Payments
- CGuard (Device) $1,625
- Activase (Biological) $12.44
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Vascular Neurology Doctors in Nashville
Dr. David Parrella, Md, MD
Vascular Neurology — Payments: $6,720
Phaniraj Iyengar, Md, MD
Vascular Neurology — Payments: $1,504
Jillian Berkman, Md, MD
Vascular Neurology — Payments: $203.73
Dennis Cole, Md, MD
Vascular Neurology — Payments: $129.82
Zunir Chaudhry, Md, MD
Vascular Neurology — Payments: $58.43